# Mesh Bio

> Mesh Bio is a Singapore-based health deep-tech company that uses digital twin technology and predictive analytics to help clinicians detect and manage chronic diseases earlier. Its DARA platform automates health-screening report generation and risk stratification, while HealthVector Diabetes - approved as a Software as a Medical Device by Singapore's Health Sciences Authority - forecasts diabetes complications years before onset. Founded in 2018 by Andrew Wu and Arsen Batagov, the company serves more than 40 healthcare groups across Asia and has assessed over 300,000 patients.

- **Founded:** 2018
- **Headquarters:** Singapore
- **Founders:** Andrew Wu (Co-Founder and CEO), Arsen Batagov (Co-Founder and CTO), Melvin Heng (Co-Founder / Physician and Hospital Administrator)
- **Team size:** ~28 employees
- **Products:** DARA, HealthVector Diabetes, Digital Twin Health Intelligence
- **Notable:** HSA approval of HealthVector Diabetes as a Software as a Medical Device (October 2023), Raised US$3.5M Series A led by East Ventures (January 2024), DARA platform deployed across 120+ medical centers in Singapore, Malaysia and Indonesia

## Products & services

- **DARA** — AI-powered platform that automates health-screening report generation, risk stratification, result interpretation, referral optimization and clinical decision support. Reduces manual report generation by up to 90% and is deployed across 120+ medical centers.
- **HealthVector Diabetes** — Predictive disease-progression tool that models diabetes complications and personalized risk. Approved by Singapore's Health Sciences Authority as a Software as a Medical Device (SaMD) in October 2023.
- **Digital Twin Health Intelligence** — Virtual models of a patient's health built from multidimensional data (bloodwork, heart rate, weight and more) to detect and predict progression across diabetes, kidney disease, cardiovascular disease, hypertension, myocardial infarction and stroke - up to 10 years before clinical diagnosis.

## Achievements

- HSA approval of HealthVector Diabetes as a Software as a Medical Device (October 2023)
- Raised US$3.5M Series A led by East Ventures (January 2024)
- DARA platform deployed across 120+ medical centers in Singapore, Malaysia and Indonesia
- 300,000+ patients assessed and 40+ healthcare groups onboarded
- Forbes Asia '100 to Watch' recognition
- OCBC Emerging Enterprise Award recognition

## Latest updates

- **2024-01** — Closed US$3.5 million Series A led by East Ventures to scale digital twin technologies across Southeast Asia, Hong Kong, Indonesia and the Philippines.
- **2023-10** — HealthVector Diabetes received Singapore HSA clearance as a Software as a Medical Device and entered implementation pilots at SGH, TTSH and polyclinics.
- **2021-10** — Raised US$1.8 million seed round to accelerate DARA rollout across Southeast Asia and Hong Kong.

## Links

- Website: https://meshbio.com
- LinkedIn: https://www.linkedin.com/company/meshbio
- Instagram: https://www.instagram.com/meshbio
- Facebook: https://www.facebook.com/meshbio

---

Profile page: https://yespress.io/mesh-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-27